Efficacy, Safety, and Tolerability of AVP-786 for the Treatment of Agitation in Participants With Dementia of the Alzheimer's Type

NCT02442778 · clinicaltrials.gov ↗

PHASE3

Phase

COMPLETED

Status

522

Enrollment

INDUSTRY

Sponsor class

Conditions

Agitation in Participants With Dementia of the Alzheimer's Type

Interventions

DRUG: AVP-786-18
DRUG: Placebo
DRUG: AVP-786-28
DRUG: AVP-786-42.63

Sponsor

Otsuka Pharmaceutical Development & Commercialization, Inc.